论文部分内容阅读
目的观察参麦注射液减轻卡培他滨所致手足综合征的的临床疗效。方法采用对比研究分析,将采用卡培他滨单药化疗的晚期恶性肿瘤212例患者分为治疗组及对照组,每组106例,2组患者均给予卡培他滨单药化疗,剂量2500mg/(m2.d),分早晚2次餐后服用,连续14d,2周期观察疗效。治疗组予参麦注射液60ml,对照组予维生素B6200mg,均每日1次静脉滴注,治疗2周。观察2组手足综合征发生率。结果治疗组手足综合征发生率44.3%(47/106),其中Ⅰ、Ⅱ、Ⅲ度手足综合征的发生率分别为23.6%、17.9%、2.8%;对照组发生率67.0%,其中Ⅰ、Ⅱ、Ⅲ度手足综合征的发生率分别为34.0%、27.3%、5.7%。治疗组优于对照组,差异有统计学意义(χ2=11.127,P<0.05)。结论参麦注射液可降低卡培他滨所致的手足综合征发生率或减轻其症状。
Objective To observe the clinical curative effect of Shenmai injection in relieving hand-foot syndrome caused by capecitabine. Methods A comparative study of 212 patients with advanced malignancy treated with capecitabine monotherapy was divided into treatment group and control group, with 106 patients in each group and 2 patients given capecitabine monotherapy with a dosage of 2500 mg /(m2.d), divided into 2 times morning and evening meal after taking, continuous 14d, 2 cycles observed efficacy. The treatment group to Shenmai injection 60ml, the control group to vitamin B6200mg, were daily intravenous infusion for 2 weeks. The incidence of hand-foot syndrome was observed in two groups. Results The incidence of hand-foot syndrome was 44.3% (47/106) in the treatment group. The incidence of hand, foot and mouth syndrome was 23.6%, 17.9% and 2.8% respectively in the treatment group and 67.0% in the control group, of which Ⅰ, Ⅱ, Ⅲ degree hand-foot syndrome were 34.0%, 27.3%, 5.7%. The treatment group was better than the control group, the difference was statistically significant (χ2 = 11.127, P <0.05). Conclusion Shenmai injection can reduce the incidence of or reduce the incidence of hand-foot syndrome caused by capecitabine.